Comprehensive Clinicopathologic, Immunohistochemical, and Genomic Profiling of Sporadic Ampullary Somatostatin-producing D-cell Neuroendocrine Tumors Identifies Recurrent HRAS Hotspot Mutations
Ampullary somatostatin-producing D-cell neuroendocrine tumors are rare neoplasms that may be associated with type 1 neurofibromatosis. The molecular features of sporadic ampullary somatostatin-producing D-cell neuroendocrine tumors (SAMSOM-NETs) remain poorly characterized. We performed an integrated morphological, immunohistochemical, and genomic analysis of a multicenter series of SAMSOM-NETs. Eleven cases were included (73% male; median age: 63 years). All six patients who underwent lymphadenectomy were staged as pN1, and liver metastases were found in three cases; however, no tumor-related deaths occurred (median follow-up: 104 months). Common histologic features that can pose diagnostic challenges in the differential diagnosis with adenocarcinoma included a tubulo-glandular architecture (100%), periodic Acid-Schiff (PAS)-positive intraluminal mucin (73%), MUC1 expression (100%), and carcinoembryonic antigen (45%) expression. All tumors exhibited dot-like cytoplasmic reactivity for cytokeratins (CK) CAM5.2 or CK AE1/AE3, and 82% were CK7-positive. ISL1 and PDX1 were diffusely expressed in all cases, while CDX2 was positive in 54% and ARX showed only focal expression in four tumors. Genomic profiling revealed microsatellite stability and low tumor mutational burden. Alterations in the RAS pathway, including HRAS mutations (4 cases, 36%), a KRAS mutation (1 case), and NF1 alterations (one case), were identified in 54% of cases and in all tumors with liver metastases. Additional molecular findings included a CDK12 splice-site alteration and an NTRK3::PRDM4 fusion. Potentially actionable alterations affecting kinase-related pathways were detected in 64% of tumors. Our findings support SAMSOM-NET as a peculiar neuroendocrine tumor subtype showing distinctive histologic and molecular characteristics with potential diagnostic and therapeutic implications.
Authors
- Federica Grillo (ORCID: https://orcid.org/0000-0001-6477-3182)
- Silvia Uccella (ORCID: https://orcid.org/0000-0002-5714-7295)
- P. Parente
- Marco Paulli (ORCID: https://orcid.org/0000-0003-2454-5980)
- Andrea Peri (ORCID: https://orcid.org/0000-0002-5911-0218)
- Stefano La Rosa (ORCID: https://orcid.org/0000-0003-1941-2403)
- Erica Travaglino (ORCID: https://orcid.org/0000-0003-4985-339X)
- Mauro Lecca (ORCID: https://orcid.org/0009-0004-0577-5259)
- Matteo Fassan (ORCID: https://orcid.org/0000-0001-6515-5482)
- Edoardo Errichiello (ORCID: https://orcid.org/0000-0001-6346-1988)
- Paola Spaggiari (ORCID: https://orcid.org/0000-0003-2905-1736)
- Antonio Di Sabatino (ORCID: https://orcid.org/0000-0002-0302-8645)
- Anna Caterina Milanetto (ORCID: https://orcid.org/0000-0002-3042-4360)
- Alessandro Zerbi
- Frediano Inzani
- Tommaso Orione
- Alessandro Vanoli
Institutions
- University of Insubria (IT)
- Humanitas University (IT)
- University of Padua (IT)
- University of Pavia (IT)
- Ospedali Riuniti di Foggia (IT)
- Saint Camillus International University of Health and Medical Sciences (IT)
- Fondazione Istituto Neurologico Nazionale Casimiro Mondino (IT)
- Istituto Oncologico Veneto (IT)
- Ospedale Policlinico San Martino (IT)
- Policlinico San Matteo Fondazione (IT)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- American Association for the Surgery of Trauma (US)
- IRCCS Humanitas Research Hospital (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Endocrine Pathology
- Published
- 2026-09-12
- DOI
- https://doi.org/10.1007/s12022-026-09934-y
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fondazione IRCCS Policlinico San Matteo
- Dipartimenti di Eccellenza
- Ministero della Salute
- Ministero dell’Istruzione, dell’Università e della Ricerca
- Università degli Studi di Pavia
- Università Cattolica del Sacro Cuore